SCHEMBL7067916

SCHEMBL7067916

CC(=O)c1c(OCC=C(C)C)ccc2c(=O)c(C)c(-c3ccccc3)oc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
PPARG P37231 1/20 0.42
ALDH1A1 P00352 5/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 1/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MAOB P27338 3/20 0.42
MAOA P21397 2/20 0.42
LMNA P02545 5/20 0.42
MAPT P10636 4/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CYP1A2 P05177 1/20 0.41
CHRM2 P08172 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
ADORA3 P0DMS8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7068041 0.89 ALDH1A1 (0.44) KDM4EALDH1A1CYP3A4CYP2C9TSHR
SCHEMBL7073297 0.89 MAOB (0.43) KDM4EPPARGALDH1A1CYP3A4CYP2C9
SCHEMBL7070586 0.86 KDM4E (0.49) KDM4EALDH1A1CYP3A4CYP2C9TSHR
SCHEMBL7075613 0.85 MAOB (0.42) ALDH1A1MAOBMAOALMNAMAPT
SCHEMBL7074913 0.84 LMNA (0.45) KDM4EPPARGALDH1A1CYP3A4TDP1
SCHEMBL7069986 0.84 ABCB1 (0.46) MAOBMAOALMNAMAPT
SCHEMBL7073031 0.83 ALDH1A1 (0.52) KDM4EALDH1A1CYP3A4CYP2C9TSHR
SCHEMBL7073603 0.83 KDM4E (0.43) KDM4EALDH1A1CYP3A4CYP2C9TSHR
SCHEMBL7072240 0.83 ALOX5 (0.50) ALDH1A1LMNAMAPTGAASMN1; SMN2
SCHEMBL7073740 0.80 MAOA (0.51) KDM4EALDH1A1MAOALMNACA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6620842-B2 Chalcones INDENA SPA (IT) 2003-09-16 US disclosed
EP-1212315-B1 NOVEL CHALCONES INDENA SPA (IT) 2003-03-26 EP disclosed
US-20030055056-A1 For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth INDENA S.P.A. (IT) 2003-03-20 US disclosed
EP-1212315-A1 NOVEL CHALCONES INDENA S.p.A. (IT) 2002-06-12 EP disclosed
WO-2001017988-A1 NOVEL CHALCONES INDENA S.P.A. (IT) 2001-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055056-A1 For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth HDGF, MKI67, HPD KDM4E 397/4885PPARG 4419/4885ALDH1A1 2113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.